JP Morgan Chase
BTTX

JP Morgan Chase’s Better Therapeutics, Inc. Common Stock BTTX Stock Holding History

JP Morgan Chase’s Portfolio BTTX Stock Details BTTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-13
Closed -$5 – 7987
2023
Q3 		$5 Buy
+13
New +$9 ﹤0.01% 7367

Other funds holding BTTX

MI
MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CIAS
Capital Investment Advisory Services Raleigh, North Carolina $1.62B AUM 27.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Corient Private Wealth
Corient Private Wealth Miami, Florida $72.2B AUM 27.85% 1-Year Est. Return

JP Morgan Chase's BTTX Position: Q4 2023 in Review

JP Morgan Chase sold out of Better Therapeutics, Inc. Common Stock (BTTX) in Q4 2023, closing a stake of 13 shares — an estimated $5 sold.

JP Morgan Chase first reported a position in BTTX in Q3 2023 and held it in 1 quarter. The position peaked at $5 in Q3 2023. 22 funds tracked by Wall St. Rank hold BTTX as of Q4 2023.

  • JP Morgan Chase reported no remaining Better Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • JP Morgan Chase sold 13 Better Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $5.
  • JP Morgan Chase first reported a position in Better Therapeutics, Inc. Common Stock in Q3 2023 and held it in 1 quarter.
  • JP Morgan Chase's Better Therapeutics, Inc. Common Stock position peaked at $5 in Q3 2023.
  • 22 funds tracked by Wall St. Rank held Better Therapeutics, Inc. Common Stock as of Q4 2023.

Based on JP Morgan Chase's 13F filing for Q4 2023, filed 12 Feb 2024.